GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (FRA:3D7) » Definitions » Equity-to-Asset

Willow Biosciences (FRA:3D7) Equity-to-Asset : 0.52 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Willow Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Willow Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €2.35 Mil. Willow Biosciences's Total Assets for the quarter that ended in Dec. 2023 was €4.56 Mil. Therefore, Willow Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.52.

The historical rank and industry rank for Willow Biosciences's Equity-to-Asset or its related term are showing as below:

FRA:3D7' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.23   Med: 0.54   Max: 0.9
Current: 0.52

During the past 13 years, the highest Equity to Asset Ratio of Willow Biosciences was 0.90. The lowest was -0.23. And the median was 0.54.

FRA:3D7's Equity-to-Asset is ranked worse than
58.14% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs FRA:3D7: 0.52

Willow Biosciences Equity-to-Asset Historical Data

The historical data trend for Willow Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences Equity-to-Asset Chart

Willow Biosciences Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 -0.03 0.85 0.90 0.52

Willow Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.87 0.74 0.68 0.52

Competitive Comparison of Willow Biosciences's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's Equity-to-Asset falls into.



Willow Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Willow Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.349/4.561
=0.52

Willow Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.349/4.561
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences  (FRA:3D7) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Willow Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Willow Biosciences (FRA:3D7) Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. Geographically, it derives a majority of its revenue from Canada.

Willow Biosciences (FRA:3D7) Headlines

No Headlines